GeoVax Labs, Inc. (GOVX)
| Market Cap | 36.64M |
| Revenue (ttm) | 1.22M |
| Net Income (ttm) | -3.93M |
| Shares Out | 5.33M |
| EPS (ttm) | -2.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $5.95 |
| Previous Close | $6.30 |
| Change ($) | -0.35 |
| Change (%) | -5.56% |
| Day's Open | 5.81 |
| Day's Range | 5.56 - 6.09 |
| Day's Volume | 516,443 |
| 52-Week Range | 2.56 - 8.71 |
Conference call to be held Thursday, May 6, at 4:30 p.m. Eastern Time
Therapeutic Vaccine Would Address Medical Need of Over 250 Million Worldwide
COVID-19 Vaccine Designed as Single-Dose Against Multiple Strains
Conference call to be held Wednesday, March 24, at 8:00 a.m. Eastern Time
GeoVax Chairman & CEO David Dodd to Present Corporate Overview
Filings Made in Corporate Focus Areas of SARS-CoV-2 and Immuno-Oncology
Virtual Conference to be Held March 9-10, 2021
Atlanta, GA, Feb. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines a...
ATLANTA, GA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines aga...
GeoVax (NASDAQ: GOVX) shares are trading sharply higher on Monday after the company announced it was awarded an NIH grant to advance its COVID-19 vaccine development. GeoVax is a U.S.-based clinical-sta...
Company Focused on Single-dose Vaccine Against Multiple COVID Strains
GeoVax Also Participating in BIO@JPM During “J.P. Morgan Week 2021”
GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript
GeoVax Labs, Inc.'s (GOVX) CEO David Dodd on Q3 2020 Results - Earnings Call Transcript
Public Offering Completed in September 2020 Provides Resources to Accelerate COVID-19 Vaccine and Immuno-Oncology Programs
Conference call to be held Friday, November 6, at 8:15 a.m. Eastern Time
ATLANTA, GA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vac...
GeoVax Labs (GOVX) news for Monday includes a deal with the National Institutes of Health to develop a vaccine for the novel coronavirus. The post GeoVax Labs News: GOVX Stock Flies 18% on NIH COVID-19 ...
Shares of GeoVax Labs Inc. were up 12.8% in trading on Monday after the company announced a patent and material licensing deal with the National Institutes of Health for COVID-19 vaccine development. As...
ATLANTA, GA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vacc...
ATLANTA, GA, Sept. 29, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and...
ATLANTA, GA, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies an...
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and... [Read more...]
| Industry Biotechnology | Founded 2001 |
| CEO David Dodd | Employees 7 |
| Stock Exchange NASDAQ | Ticker Symbol GOVX |
Financial Performance
In 2020, GeoVax Labs's revenue was $1.82 million, an increase of 55.09% compared to the previous year's $1.18 million. Losses were -$2.96 million, 24.8% more than in 2019.
Analyst Forecasts
According to one analyst, the rating for GeoVax Labs stock is "Buy" and the 12-month stock price forecast is 8.00.